erdafitinib

{
  "id": "MLC-T-ONC-002946",
  "term": "erdafitinib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat adults with urothelial cancer (a type of bladder or urinary tract cancer) that has spread and has an abnormal FGFR3 gene. It is used in patients whose cancer got worse during or after treatment with at least one type of systemic therapy. It is also being studied in the treatment of other types of cancer. Erdafitinib blocks a protein called FGFR, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called Balversa.",
    "An orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Upon oral administration, erdafitinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways and thus the inhibition of tumor cell proliferation and tumor cell death in FGFR-overexpressing tumor cells. FGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival."
  ],
  "synonyms": [
    "Balversa",
    "pan-FGFR tyrosine kinase inhibitor JNJ-42756493"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/erdafitinib/"
}